Online inquiry

IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3902MR)

This product GTTS-WQ3902MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3902MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9421MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ9216MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ2917MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ3762MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ10456MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ9014MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ15287MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ5953MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CL-2C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW